Stephen J Farr

USPTO Granted Patents = 31 (Patent Applications = 22)

EPO Patents = 8 (Patent Applications = 11)

Average Co-Inventor Count = 2.4

ph-index = 17

Forward Citations = 1,177(Granted Patents)

Location History:

Orinda, CA (US) (1998 - 2023)
Emeryville, CA (US) (2022 - 2023)

Company Filing History:

Zogenix International Limited

Years Active: 1998-2023

Loading Chart...

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11786487 - Formulation for inhibiting formation of 5-HTagonists and methods of using same (2023-10-17),

2. 11759440 - Formulation for inhibiting formation of 5-HTagonists and methods of using same (2023-09-19),

3. 11673852 - Metabolism resistant fenfluramine analogs and methods of using the same (2023-06-13),

4. 11406606 - Formulation for inhibiting formation of 5-HT2B agonists and methods of using same (2022-08-09),

5. 11325882 - Metabolism resistant fenfluramine analogs and methods of using the same (2022-05-10),

6. 11040018 - Formulation for inhibiting formation of 5-HT2B agonists and methods of using same (2021-06-22),

7. 10603290 - Formulation for inhibiting formation of 5-HTagonists and methods of using same (2020-03-31),

8. 9186461 - Viscous formulations and their use in needle-free injection (2015-11-17),

9. 8876758 - Viscous formulations and their use in needle-free injection (2014-11-04),

10. 8066661 - Viscous formulations and their use in needle-free injection (2011-11-29),

11. 7490603 - Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin (2009-02-17),

12. 7448375 - Method of treating diabetes mellitus in a patient (2008-11-11),

13. 7278419 - Method for treating diabetes mellitus in a patient (2007-10-09),

14. 7028686 - Inhaled insulin dosage control delivery enhanced by controlling total inhaled volume (2006-04-18),

15. 7021309 - Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin (2006-04-04),

Title: **Stephen J. Farr: Innovator in Drug Formulation**

Introduction

Stephen J. Farr, a distinguished inventor based in Orinda, California, holds a remarkable portfolio of 31 patents. His work primarily focuses on enhancing drug formulations to improve safety and efficacy. His latest inventions showcase his commitment to addressing significant health concerns through innovative solutions.

Latest Patents

Among Farr's latest patents is a formulation aimed at inhibiting the formation of 5-HT agonists, which are known to produce adverse side effects. This patent details a method where a first drug, such as fenfluramine, is administered alongside a second drug, such as cannabidiol, which acts as a CYP inhibitor. By modulating the formation of harmful metabolites, this combination enhances the safety of the initial drug, representing a significant advancement in pharmaceutical innovation.

Career Highlights

Farr's career spans various reputable companies, including Aradigm Corporation and Zogenix International Limited. His experience in these organizations has allowed him to contribute to the development of groundbreaking drug therapies and formulations. Farr's dedication to improving public health through innovation has earned him recognition among his peers in the pharmaceutical industry.

Collaborations

Throughout his career, Farr has collaborated with notable individuals such as Reid M. Rubsamen and Igor Gonda. These partnerships have played a crucial role in the development of his patented inventions, expanding the scope of his impact within the field of drug formulation.

Conclusion

In conclusion, Stephen J. Farr exemplifies the essence of innovation in pharmacology. With 31 patents to his name, his contributions to enhancing drug safety are invaluable. Through collaborative efforts and a focus on addressing complex health issues, Farr continues to pave the way for future advancements in the pharmaceutical industry. His work not only highlights the importance of safety in drug formulations but also reinforces the significance of creativity and teamwork in scientific research.

This text is generated by artificial intelligence and may not be accurate.